---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-072534"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:47:00.745011+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alaunos shareholders approve reverse stock split (1:5-1:15) and authorized share increase to 50M

## Summary
- Stockholders approved reverse stock split at ratio between 1-for-5 and 1-for-15, at Board's discretion, effective June 12, 2024.
- Authorized shares of common stock increased from 34,666,667 to 50,000,000.
- Five directors elected: Curtis Hogue Jr., Robert Hofmeister, Robert Postma, Jaime Vieser, Holger Weis.
- Advisory vote on executive compensation passed with 1,851,846 for and 1,032,789 against.
- Ratification of RSM US LLP as independent auditor for FY 2024 approved.

## SEC filing metadata
- accession: 0000950170-24-072534
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.03, 5.07, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017024072534/0000950170-24-072534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017024072534/tcrt-20240606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-072534
- JSON: https://secwatch.observer/filing/0000950170-24-072534.json
- Plain text: https://secwatch.observer/filing/0000950170-24-072534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.